Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-conjugating enzyme E2 N-like (UBE2NL) is an intronless gene annotated as a member of the E2 ubiquitin-conjugating enzyme family, but it is primarily annotated as a polymorphic pseudogene in humans; some individuals have an allele encoding a full-length protein, while others have a non-functional allele with a premature stop codon[1][3][2]. The protein is 91% identical to UBE2N, a core E2 enzyme, but the function of UBE2NL remains uncharacterized and there is no established role in human disease or therapeutic targeting[3][2][5][1]. Most recent literature classifies UBE2NL as a pseudogene with uncertain protein-coding capability and unknown biological function[1][2][3]; there are no reported interacting drugs, disease links, or validated clinical biomarker data for this gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 N-like (UBE2NL).